**David Amsellem, Piper Sandler & Co., Research Division**
All right. Well, good afternoon, everyone. This is David Amsellem from the Piper Sandler Biopharma research team. I know it’s a really busy day, and we’re all trying to get through the heart—or really the tail end—of the 3Q earnings cycle.
We have a lot to cover today with Aquestive, and I think this will be a really informative and insightful hour spent with the Aquestive Therapeutics senior leadership team.
We have the whole team here:
– Dan Barber, President and CEO
– Ernie Toth, CFO
– Gary Slatko, Chief Medical Officer
– Melina Cioffi, SVP, Regulatory Affairs
– Cassie Jung, Chief Operating Officer
– Sherry Korczynski, Chief Commercial Officer
Thanks so much to all of you for joining. I know many of you are at the ACAAI meeting down in Florida, where there will be data presented in the coming days. It’s a big forum for all things related to Anaphylm.
—
With that, I’d like to turn it over to Dan for a quick introduction. Also, as I typically do with these sessions, I’d like to start with a question. Looking more broadly at the company, obviously, Anaphylm and getting Anaphylm right is the top priority. But, longer term, how do you balance that top priority with other clinical and commercial initiatives?
https://seekingalpha.com/article/4840121-aquestive-therapeutics-inc-aqst-discusses-anaphylm-regulatory-progress-commercial-strategy?source=feed_all_articles